A Phase 1, multicenter, open-label, non-randomized, dose-escalation study with backfill cohorts of KK2223 in participants with relapsed or refractory T-cell non-Hodgkin lymphoma.
Principal Investigator
Dott. Umberto Vitolo
Contact Information for Access
Phase
FASE I
Status
IN ATTIVAZIONE
Objective of the study
To evaluate the safety and tolerability and determine the MTD (Part 1) of KK2223 in participants with relapsed or refractory PTCL or CTCL.
T-cell NHL (PTCL or CTCL)
Non-Hodgkin lymphoma
ClinicalTrials.gov ID NCT07192471
Sponsor Kyowa Kirin, Inc.
Pathologies
Onco-hematological (hematological cancers/malignancies)
Medication
KK2223 (anti-CCR4 ADC)
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
View the full study Back to search page